메뉴 건너뛰기




Volumn 4, Issue 2, 2013, Pages 285-308

Using exenatide twice daily or insulin in clinical practice: Results from choice

Author keywords

Diabetes mellitus; Exenatide; Injectable therapy; Insulin; Type 2

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA GLUCOSIDASE INHIBITOR; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; HEMOGLOBIN A1C; INSULIN; LIRAGLUTIDE; LONG ACTING INSULIN; MEGLITINIDE; METFORMIN; SHORT ACTING INSULIN; SULFONYLUREA;

EID: 84892887494     PISSN: 18696953     EISSN: 18696961     Source Type: Journal    
DOI: 10.1007/s13300-013-0037-8     Document Type: Article
Times cited : (12)

References (34)
  • 1
    • 84864285795 scopus 로고    scopus 로고
    • Management of hyperglycaemia in type 2 diabetes: A patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
    • Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2012;55:1577-96.
    • (2012) Diabetologia , vol.55 , pp. 1577-1596
    • Inzucchi, S.E.1    Bergenstal, R.M.2    Buse, J.B.3
  • 2
    • 37349008890 scopus 로고    scopus 로고
    • Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: A multinational, randomized, open-label, two-period, crossover noninferiority trial
    • Barnett AH, Burger J, Johns D, et al. Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial. Clin Ther. 2007;29:2333-48.
    • (2007) Clin Ther , vol.29 , pp. 2333-2348
    • Barnett, A.H.1    Burger, J.2    Johns, D.3
  • 3
    • 26944477362 scopus 로고    scopus 로고
    • Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: A randomized trial
    • Heine RJ, Van Gaal LF, Johns D, et al. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med. 2005;143:559-69.
    • (2005) Ann Intern Med , vol.143 , pp. 559-569
    • Heine, R.J.1    van Gaal, L.F.2    Johns, D.3
  • 4
    • 34247195226 scopus 로고    scopus 로고
    • A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: A non-inferiority study
    • Nauck MA, Duran S, Kim D, Johns D, Northrup J, Festa A. A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. Diabetologia. 2007;50:259-67.
    • (2007) Diabetologia , vol.50 , pp. 259-267
    • Nauck, M.A.1    Duran, S.2    Kim, D.3    Johns, D.4    Northrup, J.5    Festa, A.6
  • 6
    • 79955736485 scopus 로고    scopus 로고
    • Pragmatic trials-guides to better patient care?
    • Ware JH, Hamel MB. Pragmatic trials-guides to better patient care? N Engl J Med. 2011;364:1865-7.
    • (2011) N Engl J Med , vol.364 , pp. 1865-1867
    • Ware, J.H.1    Hamel, M.B.2
  • 8
    • 0037258518 scopus 로고    scopus 로고
    • Observational research methods. Research design II: Cohort, cross sectional, and case-control studies
    • Mann CJ. Observational research methods. Research design II: cohort, cross sectional, and case-control studies. Emerg Med J. 2003;20:54-60.
    • (2003) Emerg Med J , vol.20 , pp. 54-60
    • Mann, C.J.1
  • 9
    • 84863903161 scopus 로고    scopus 로고
    • Patients with type 2 diabetes initiating exenatide BID or insulin in clinical practice: CHOICE study
    • Matthaei S, Reaney M, Mathieu C, et al. Patients with type 2 diabetes initiating exenatide BID or insulin in clinical practice: CHOICE study. Diabetes Ther. 2012;3:6.
    • (2012) Diabetes Ther , vol.3 , pp. 6
    • Matthaei, S.1    Reaney, M.2    Mathieu, C.3
  • 10
    • 67649321802 scopus 로고    scopus 로고
    • Characteristics of patients with type 2 diabetes mellitus initiating insulin therapy: Baseline data from the INSTIGATE study
    • Jones S, Benroubi M, Castell C, et al. Characteristics of patients with type 2 diabetes mellitus initiating insulin therapy: baseline data from the INSTIGATE study. Curr Med Res Opin. 2009;25:691-700.
    • (2009) Curr Med Res Opin , vol.25 , pp. 691-700
    • Jones, S.1    Benroubi, M.2    Castell, C.3
  • 11
    • 33845788010 scopus 로고    scopus 로고
    • Statistical and regulatory issues with the application of propensity score analysis to nonrandomized medical device clinical studies
    • Yue LQ. Statistical and regulatory issues with the application of propensity score analysis to nonrandomized medical device clinical studies. J Biopharm Stat. 2007;17:1-13.
    • (2007) J Biopharm Stat , vol.17 , pp. 1-13
    • Yue, L.Q.1
  • 12
    • 83655184782 scopus 로고    scopus 로고
    • 1c of >7% without weight gain or hypoglycaemia in type 2 diabetes: A meta-analysis of the liraglutide clinical trial programme
    • Zinman B, Schmidt WE, Moses A, et al. Achieving a clinically relevant composite outcome of an HbA1c of >7% without weight gain or hypoglycaemia in type 2 diabetes: a meta-analysis of the liraglutide clinical trial programme. Diabetes Obes Metab. 2012;14:77-82.
    • (2012) Diabetes Obes Metab , vol.14 , pp. 77-82
    • Zinman, B.1    Schmidt, W.E.2    Moses, A.3
  • 13
    • 84899784383 scopus 로고    scopus 로고
    • TREAT Study Investigators. Costs and clinical outcomes after 24 months of insulin therapy in patients with type 2 diabetes: Results from the TREAT study
    • Lisbon, Portugal, 12-16 September
    • Benroubi M, Schmitt H, Cleall SP, et al., TREAT Study Investigators. Costs and clinical outcomes after 24 months of insulin therapy in patients with type 2 diabetes: results from the TREAT study. Poster presented at the 47th European Association for the Study of Diabetes (EASD) Annual Meeting, Lisbon, Portugal, 12-16 September 2011.
    • (2011) Poster Presented At the 47th European Association For the Study of Diabetes (EASD) Annual Meeting
    • Benroubi, M.1    Schmitt, H.2    Cleall, S.P.3
  • 14
    • 0034641568 scopus 로고    scopus 로고
    • Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study
    • Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321:405-12.
    • (2000) BMJ , vol.321 , pp. 405-412
    • Stratton, I.M.1    Adler, A.I.2    Neil, H.A.3
  • 15
    • 84862302997 scopus 로고    scopus 로고
    • Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): An open-label, randomised controlled trial
    • Gallwitz B, Guzman J, Dotta F, et al. Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open-label, randomised controlled trial. Lancet. 2012;379:2270-8.
    • (2012) Lancet , vol.379 , pp. 2270-2278
    • Gallwitz, B.1    Guzman, J.2    Dotta, F.3
  • 16
    • 35548947584 scopus 로고    scopus 로고
    • Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes
    • 4-T Study Group
    • Holman RR, Thorne KI, Farmer AJ, 4-T Study Group, et al. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med. 2007;357:1716-30.
    • (2007) N Engl J Med , vol.357 , pp. 1716-1730
    • Holman, R.R.1    Thorne, K.I.2    Farmer, A.J.3
  • 17
    • 70350534273 scopus 로고    scopus 로고
    • Three-year efficacy of complex insulin regimens in type 2 diabetes
    • 4-T Study Group
    • Holman RR, Farmer AJ, Davies MJ, 4-T Study Group, et al. Three-year efficacy of complex insulin regimens in type 2 diabetes. N Engl J Med. 2009;361:1736-47.
    • (2009) N Engl J Med , vol.361 , pp. 1736-1747
    • Holman, R.R.1    Farmer, A.J.2    Davies, M.J.3
  • 18
    • 18144401971 scopus 로고    scopus 로고
    • Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes
    • DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care. 2005;28:1092-100.
    • (2005) Diabetes Care , vol.28 , pp. 1092-1100
    • Defronzo, R.A.1    Ratner, R.E.2    Han, J.3    Kim, D.D.4    Fineman, M.S.5    Baron, A.D.6
  • 19
    • 7444228521 scopus 로고    scopus 로고
    • Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes
    • Exenatide-113 Clinical Study Group
    • Buse JB, Henry RR, Han J, Exenatide-113 Clinical Study Group, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care. 2004;27:2628-35.
    • (2004) Diabetes Care , vol.27 , pp. 2628-2635
    • Buse, J.B.1    Henry, R.R.2    Han, J.3
  • 20
    • 17144371646 scopus 로고    scopus 로고
    • Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea
    • Kendall DM, Riddle MC, Rosenstock J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care. 2005;28:1083-91.
    • (2005) Diabetes Care , vol.28 , pp. 1083-1091
    • Kendall, D.M.1    Riddle, M.C.2    Rosenstock, J.3
  • 21
    • 81855221189 scopus 로고    scopus 로고
    • Exenatide BID Observational Study (ExOS): Results for primary and secondary endpoints of a prospective research study to evaluate the clinical effectiveness of exenatide BID use in patients with type 2 diabetes in a real-world setting
    • Bergenstal RM, Garrison LP, Miller LA, et al. Exenatide BID Observational Study (ExOS): results for primary and secondary endpoints of a prospective research study to evaluate the clinical effectiveness of exenatide BID use in patients with type 2 diabetes in a real-world setting. Curr Med Res Opin. 2011;27:2335-42.
    • (2011) Curr Med Res Opin , vol.27 , pp. 2335-2342
    • Bergenstal, R.M.1    Garrison, L.P.2    Miller, L.A.3
  • 22
    • 79951668719 scopus 로고    scopus 로고
    • Exenatide bid observational study (ExOS): Baseline population characteristics of a prospective research study to evaluate the clinical effectiveness of exenatide bid use in patients with type 2 diabetes in a real-world setting
    • Bergenstal RM, Garrison LP Jr, Wintle M, et al. Exenatide bid observational study (ExOS): baseline population characteristics of a prospective research study to evaluate the clinical effectiveness of exenatide bid use in patients with type 2 diabetes in a real-world setting. Curr Med Res Opin. 2011;27:531-40.
    • (2011) Curr Med Res Opin , vol.27 , pp. 531-540
    • Bergenstal, R.M.1    Garrison Jr., L.P.2    Wintle, M.3
  • 23
    • 70450203583 scopus 로고    scopus 로고
    • Six-month outcomes on A1C and cardiovascular risk factors in patients with type 2 diabetes treated with exenatide in an ambulatory care setting
    • Brixner DI, McAdam-Marx C, Ye X, et al. Six-month outcomes on A1C and cardiovascular risk factors in patients with type 2 diabetes treated with exenatide in an ambulatory care setting. Diabetes Obes Metab. 2009;11:1122-30.
    • (2009) Diabetes Obes Metab , vol.11 , pp. 1122-1130
    • Brixner, D.I.1    McAdam-Marx, C.2    Ye, X.3
  • 24
    • 78449248761 scopus 로고    scopus 로고
    • ABCD Nationwide Exenatide Audit Contributors. The Association of British Clinical Diabetologists (ABCD) nationwide exenatide audit
    • Ryder REJ, Thong KY, Cull ML, et al., ABCD Nationwide Exenatide Audit Contributors. The Association of British Clinical Diabetologists (ABCD) nationwide exenatide audit. Pract Diab Int. 2010;27:352-7.
    • (2010) Pract Diab Int , vol.27 , pp. 352-357
    • Ryder, R.E.J.1    Thong, K.Y.2    Cull, M.L.3
  • 26
    • 84871124257 scopus 로고    scopus 로고
    • Clinical outcomes after insulin initiation in patients with type 2 diabetes: 24-month results from INSTIGATE
    • Liebl A, Jones S, Goday A, et al. Clinical outcomes after insulin initiation in patients with type 2 diabetes: 24-month results from INSTIGATE. Diabetes Ther. 2012;3:9.
    • (2012) Diabetes Ther , vol.3 , pp. 9
    • Liebl, A.1    Jones, S.2    Goday, A.3
  • 27
    • 84873029199 scopus 로고    scopus 로고
    • AHRQ's comparative effectiveness research on oral medications for type 2 diabetes: A summary of the key findings
    • Bennett WL, Balfe LM, Faysal JM. AHRQ's comparative effectiveness research on oral medications for type 2 diabetes: a summary of the key findings. J Manag Care Pharm. 2012;18(1 Suppl. A):1-22.
    • (2012) J Manag Care Pharm , vol.18 , Issue.1 SUPPL. A , pp. 1-22
    • Bennett, W.L.1    Balfe, L.M.2    Faysal, J.M.3
  • 28
    • 69949117621 scopus 로고    scopus 로고
    • Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met + SU): A randomised controlled trial
    • Liraglutide effect and action in Diabetes 5 (LEAD-5) met + SU Study Group
    • Russell-Jones D, Vaag A, Schmitz O, Liraglutide effect and action in Diabetes 5 (LEAD-5) met + SU Study Group, et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met + SU): a randomised controlled trial. Diabetologia. 2009;52:2046-55.
    • (2009) Diabetologia , vol.52 , pp. 2046-2055
    • Russell-Jones, D.1    Vaag, A.2    Schmitz, O.3
  • 29
    • 77953859640 scopus 로고    scopus 로고
    • Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): An open-label randomised trial
    • Diamant M, Van Gaal L, Stranks S, et al. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. Lancet. 2010;375:2234-43.
    • (2010) Lancet , vol.375 , pp. 2234-2243
    • Diamant, M.1    van Gaal, L.2    Stranks, S.3
  • 30
    • 84886943101 scopus 로고    scopus 로고
    • Newer agents for blood glucose control in type 2 diabetes: Systematic review and economic evaluation
    • Waugh N, Cummins E, Royle P, et al. Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation. Health Technol Assess. 2010;14:1-248.
    • (2010) Health Technol Assess , vol.14 , pp. 1-248
    • Waugh, N.1    Cummins, E.2    Royle, P.3
  • 31
    • 84862698727 scopus 로고    scopus 로고
    • Post-marketing studies of new insulins: Sales or science?
    • Gale EA. Post-marketing studies of new insulins: sales or science? BMJ. 2012;344:e3974.
    • (2012) BMJ , vol.344
    • Gale, E.A.1
  • 32
    • 84862689505 scopus 로고    scopus 로고
    • Post-marketing observational trials and catastrophic health expenditure
    • Yudkin JS. Post-marketing observational trials and catastrophic health expenditure. BMJ. 2012;344: e3987.
    • (2012) BMJ , vol.344
    • Yudkin, J.S.1
  • 33
    • 84876893139 scopus 로고    scopus 로고
    • press release). San Diego, CA: Amylin Pharmaceuticals, Inc. c2012 (updated March 23, 2012; cited June 13, Accessed 12 Dec 2012
    • Byetta approved for use with basal insulin in Europe (press release). San Diego, CA: Amylin Pharmaceuticals, Inc. c2012 (updated March 23, 2012; cited June 13, 2012). https://investor.lilly.com/releasedetail2.cfm?ReleaseID=659089. Accessed 12 Dec 2012.
    • (2012) Byetta Approved For Use With Basal Insulin In Europe
  • 34
    • 84899864631 scopus 로고    scopus 로고
    • ABCD Nationwide Exenatide and Liraglutide Audit Contributors. ABCD Nationwide Exenatide and Liraglutide Audits
    • London, 30 March-1 April
    • Ryder RJ, Thong K, ABCD Nationwide Exenatide and Liraglutide Audit Contributors. ABCD Nationwide Exenatide and Liraglutide Audits. Oral presentation at the diabetes UK annual professional conference, London, 30 March-1 April 2011
    • (2011) Oral Presentation At the Diabetes UK Annual Professional Conference
    • Ryder, R.J.1    Thong, K.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.